Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1782048 | 0.98 | DPP4 (0.47) | DPP4MMECYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL4323492 | 0.98 | DPP4 (0.47) | DPP4MMECYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL1513992 | 0.89 | — | — | |
| SCHEMBL14691680 | 0.81 | DPP4 (0.47) | DPP4ALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL3205065 | 0.79 | DPP4 (0.40) | DPP4MMECYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL5634108 | 0.75 | MME (0.38) | DPP4MMECYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL24666314 | 0.74 | EPHX1 (0.39) | CYP2C19CYP1A2CTHEGLN1 | |
| SCHEMBL5095243 | 0.74 | TSHR (0.41) | MMECYP2C19ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL2588409 | 0.71 | MME (0.41) | MMECYP2C19ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL21752029 | 0.71 | TSHR (0.47) | DPP4MMECYP2C19ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1006122-B1 | PHENETHYLAMINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-12-03 | — | — | EP | claimed |
| EP-0813544-A4 | — | — | 1998-01-07 | — | — | EP | claimed |
| EP-0813544-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1997-12-29 | — | — | EP | claimed |
| CN-1148393-A | Bradykinin antagonist peptides incorporating N-substituted glycines | CORTECH INC (US) | 1997-04-23 | — | — | CN | claimed |
| WO-1995024422-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1995-09-14 | — | — | WO | claimed |
| CN-102206247-B | Novel peptides as NS3/NS4a serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2013-03-27 | — | — | CN | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102206247-A | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON CORP | 2011-10-05 | — | — | CN | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| CN-101792483-A | Novel peptides as inhibitors of hepatitis C virus NS 3-serine protease | SCHERING CORP | 2010-08-04 | — | — | CN | disclosed |
| EP-1481000-B1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| US-5852051-A | Dipeptide p-amidinobenzylamides with N-terminal sulfonyl or aminosulfonyl radicals | BASF AKTIENGESELLSCHAFT (DE) | 1998-12-22 | — | — | US | disclosed |
| EP-0813544-A4 | — | — | 1998-01-07 | — | — | EP | disclosed |
| EP-0813544-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5700779-A | ALLEVIATING PAIN, ASTHMA, INFLAMMATION, CEREBRAL EDEMA, CARDIOVASCULAR DYSFUNCTION | CORTECH, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0796271-A1 | NEW DIPEPTIDE P-AMIDINOBENZYLAMIDES WITH N-TERMINAL SULFONYL OR AMINOSULFONYL RADICALS | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
| CN-1148393-A | Bradykinin antagonist peptides incorporating N-substituted glycines | CORTECH INC (US) | 1997-04-23 | — | — | CN | disclosed |
| WO-1996017860-A1 | NEW DIPEPTIDE P-AMIDINOBENZYLAMIDES WITH N-TERMINAL SULFONYL OR AMINOSULFONYL RADICALS | BASF AKTIENGESELLSCHAFT (DE) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995024422-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | DPP4 26/4885MME 34/4885CYP2C19 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.